Cargando…
CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2
The ongoing SARS-CoV-2 pandemic necessitates the fast development of vaccines. Recently, viral mutants termed variants of concern (VOC) which may escape host immunity have emerged. The efficacy of spike encoding mRNA vaccines (CVnCoV and CV2CoV) against the ancestral strain and the VOC B.1.351 was t...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245475/ https://www.ncbi.nlm.nih.gov/pubmed/34193869 http://dx.doi.org/10.1038/s41467-021-24339-7 |
| _version_ | 1783716120562237440 |
|---|---|
| author | Hoffmann, Donata Corleis, Björn Rauch, Susanne Roth, Nicole Mühe, Janine Halwe, Nico Joel Ulrich, Lorenz Fricke, Charlie Schön, Jacob Kraft, Anna Breithaupt, Angele Wernike, Kerstin Michelitsch, Anna Sick, Franziska Wylezich, Claudia Hoffmann, Bernd Thran, Moritz Thess, Andreas Mueller, Stefan O. Mettenleiter, Thomas C. Petsch, Benjamin Dorhoi, Anca Beer, Martin |
| author_facet | Hoffmann, Donata Corleis, Björn Rauch, Susanne Roth, Nicole Mühe, Janine Halwe, Nico Joel Ulrich, Lorenz Fricke, Charlie Schön, Jacob Kraft, Anna Breithaupt, Angele Wernike, Kerstin Michelitsch, Anna Sick, Franziska Wylezich, Claudia Hoffmann, Bernd Thran, Moritz Thess, Andreas Mueller, Stefan O. Mettenleiter, Thomas C. Petsch, Benjamin Dorhoi, Anca Beer, Martin |
| author_sort | Hoffmann, Donata |
| collection | PubMed |
| description | The ongoing SARS-CoV-2 pandemic necessitates the fast development of vaccines. Recently, viral mutants termed variants of concern (VOC) which may escape host immunity have emerged. The efficacy of spike encoding mRNA vaccines (CVnCoV and CV2CoV) against the ancestral strain and the VOC B.1.351 was tested in a K18-hACE2 transgenic mouse model. Naive mice and mice immunized with a formalin-inactivated SARS-CoV-2 preparation were used as controls. mRNA-immunized mice develop elevated SARS-CoV-2 RBD-specific antibody and neutralization titers which are readily detectable, but significantly reduced against VOC B.1.351. The mRNA vaccines fully protect from disease and mortality caused by either viral strain. SARS-CoV-2 remains undetected in swabs, lung, or brain in these groups. Despite lower neutralizing antibody titers compared to the ancestral strain BavPat1, CVnCoV and CV2CoV show complete disease protection against the novel VOC B.1.351 in our studies. |
| format | Online Article Text |
| id | pubmed-8245475 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82454752021-07-20 CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2 Hoffmann, Donata Corleis, Björn Rauch, Susanne Roth, Nicole Mühe, Janine Halwe, Nico Joel Ulrich, Lorenz Fricke, Charlie Schön, Jacob Kraft, Anna Breithaupt, Angele Wernike, Kerstin Michelitsch, Anna Sick, Franziska Wylezich, Claudia Hoffmann, Bernd Thran, Moritz Thess, Andreas Mueller, Stefan O. Mettenleiter, Thomas C. Petsch, Benjamin Dorhoi, Anca Beer, Martin Nat Commun Article The ongoing SARS-CoV-2 pandemic necessitates the fast development of vaccines. Recently, viral mutants termed variants of concern (VOC) which may escape host immunity have emerged. The efficacy of spike encoding mRNA vaccines (CVnCoV and CV2CoV) against the ancestral strain and the VOC B.1.351 was tested in a K18-hACE2 transgenic mouse model. Naive mice and mice immunized with a formalin-inactivated SARS-CoV-2 preparation were used as controls. mRNA-immunized mice develop elevated SARS-CoV-2 RBD-specific antibody and neutralization titers which are readily detectable, but significantly reduced against VOC B.1.351. The mRNA vaccines fully protect from disease and mortality caused by either viral strain. SARS-CoV-2 remains undetected in swabs, lung, or brain in these groups. Despite lower neutralizing antibody titers compared to the ancestral strain BavPat1, CVnCoV and CV2CoV show complete disease protection against the novel VOC B.1.351 in our studies. Nature Publishing Group UK 2021-06-30 /pmc/articles/PMC8245475/ /pubmed/34193869 http://dx.doi.org/10.1038/s41467-021-24339-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Article Hoffmann, Donata Corleis, Björn Rauch, Susanne Roth, Nicole Mühe, Janine Halwe, Nico Joel Ulrich, Lorenz Fricke, Charlie Schön, Jacob Kraft, Anna Breithaupt, Angele Wernike, Kerstin Michelitsch, Anna Sick, Franziska Wylezich, Claudia Hoffmann, Bernd Thran, Moritz Thess, Andreas Mueller, Stefan O. Mettenleiter, Thomas C. Petsch, Benjamin Dorhoi, Anca Beer, Martin CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2 |
| title | CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2 |
| title_full | CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2 |
| title_fullStr | CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2 |
| title_full_unstemmed | CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2 |
| title_short | CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2 |
| title_sort | cvncov and cv2cov protect human ace2 transgenic mice from ancestral b bavpat1 and emerging b.1.351 sars-cov-2 |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245475/ https://www.ncbi.nlm.nih.gov/pubmed/34193869 http://dx.doi.org/10.1038/s41467-021-24339-7 |
| work_keys_str_mv | AT hoffmanndonata cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2 AT corleisbjorn cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2 AT rauchsusanne cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2 AT rothnicole cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2 AT muhejanine cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2 AT halwenicojoel cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2 AT ulrichlorenz cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2 AT frickecharlie cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2 AT schonjacob cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2 AT kraftanna cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2 AT breithauptangele cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2 AT wernikekerstin cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2 AT michelitschanna cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2 AT sickfranziska cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2 AT wylezichclaudia cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2 AT hoffmannbernd cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2 AT thranmoritz cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2 AT thessandreas cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2 AT muellerstefano cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2 AT mettenleiterthomasc cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2 AT petschbenjamin cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2 AT dorhoianca cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2 AT beermartin cvncovandcv2covprotecthumanace2transgenicmicefromancestralbbavpat1andemergingb1351sarscov2 |